Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Enterprise Value : NT$1,501.5 Mil (As of May. 26, 2024)

Taiwan Advance Bio-Pharmaceutical Enterprise Value Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Enterprise Value		Get a 7-Day Free Trial					1,655.48	2,319.00	1,757.06	1,680.24	1,663.50

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Enterprise Value	Get a 7-Day Free Trial															1,757.06	1,600.74	1,680.24	1,852.46	1,663.50

Competitive Comparison of Taiwan Advance Bio-Pharmaceutical's Enterprise Value

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Advance Bio-Pharmaceutical's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Enterprise Value falls into.

Taiwan Advance Bio-Pharmaceutical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Taiwan Advance Bio-Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Taiwan Advance Bio-Pharmaceutical's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Taiwan Advance Bio-Pharmaceutical's EV-to-EBIT for today is

Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$1,501.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-4.1 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Taiwan Advance Bio-Pharmaceutical's EV-to-EBITDA for today is:

Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$1,501.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$21.8 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Taiwan Advance Bio-Pharmaceutical's EV-to-Revenue for today is:

Taiwan Advance Bio-Pharmaceutical's current Enterprise Value is NT$1,501.5 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Taiwan Advance Bio-Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was NT$316.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Taiwan Advance Bio-Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Business Description